SKYSCRAPER-07 at ESMO 2025: Tira + Atezo in ESCC At ESMO 2025, SKYSCRAPER-07 showed tiragolumab+ atezolizumab missed the PFS , while atezolizumab alone improved survival in ESCC.

SKYSCRAPER-07 at ESMO 2025: Tiragolumab Plus Atezolizumab After dCRT in Locally Advanced ESCC

@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025 #ESCC #SKYSCRAPER07 #Tiragolumab #Atezolizumab #GIOnc

Interesting summary of #morpheusliver #HCC data and issues. #tigit inh. #tiragolumab + #tecentriq #avastin performed well vs. #IMBRAVE150 doublet but latter underperformed. PFS unprecedented. Exciting but await #IMBRAVE152 to confirm #livertwitter...